Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial

被引：2
|
作者：
Pohlmann, Paula R. [1 ]
Diamond, Jennifer R. [2 ]
Hamilton, Erika [3 ,4 ]
Tolaney, Sara M. [5 ]
Zhang, Wei [6 ]
Iizuka, Koho [6 ]
Foster, Paul [6 ]
Molinero, Luciana [6 ]
Funke, Roel [6 ]
Adams, Sylvia [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] NYU, Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [42] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
  • [43] Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
    Schmid, P.
    Kuemmel, S.
    Loirat, D.
    Savas, P.
    Espinosa, E.
    Boni, V
    Italiano, A.
    White, S.
    Singel, S.
    Withana, N.
    Mani, A.
    Li, S.
    Harris, A.
    Wongchenko, M.
    Sablin, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E44 - E45
  • [44] tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pier Franco
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Marc A.
    O'Shaughnessy, Joyce
    Li, Li
    Barton, Debora
    Beck, Robert M.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] COLET: A multistage, phase 2 study evaluating the safety and efficacy of a doublet regimen of cobimetinib (C) in combination with paclitaxel (P) or triplet regimens of C in combination with atezolizumab (atezo) plus either P or nab-paclitaxel (nab-P) in metastatic triple-negative breast cancer (TNBC)
    Miles, D.
    Kim, S-B
    McNally, V.
    Simmons, B.
    Wongchenko, M.
    Xu, N.
    Brufsky, A.
    CANCER RESEARCH, 2017, 77
  • [46] Impressive Remission of metastatic PDL-1 positive triple negative Breast Carcinoma with Atezolizumab and nab-Paclitaxel
    Jahn, K.
    Baum, D.
    Langanke, D.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E44 - E44
  • [47] Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC)
    Litton, J. K.
    Moulder, S. L.
    Hess, K. R.
    Damodaran, S.
    Rauch, G. M.
    Candelaria, R.
    Adrada, B. E.
    Symmans, F.
    Murthy, R. K.
    Helgason, T.
    Clayborn, A.
    Prabhakaran, S.
    Valero, V.
    Thompson, A. M.
    Mittendorf, E. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 72 - 72
  • [48] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [49] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
    Hamilton, Erika
    Lee, Arielle
    Swart, Rachel
    Newton, Gina
    O'Connell, Brenda
    Roberts, Jennifer
    Zhang, Halle
    Soliman, Hatem
    CANCER RESEARCH, 2021, 81 (04)
12345